ProPhase Labs, Inc. (NASDAQ:PRPH) major shareholder Braden Michael Leonard sold 1,695,305 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $2.30, for a total value of $3,899,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

ProPhase Labs, Inc. (NASDAQ PRPH) opened at 2.06 on Wednesday. ProPhase Labs, Inc. has a 12-month low of $1.78 and a 12-month high of $2.45. The stock’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.08. The stock has a market capitalization of $33.30 million, a PE ratio of 0.86 and a beta of 0.02.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.09) earnings per share for the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%. The business had revenue of $1.91 million for the quarter.

ProPhase Labs declared that its Board of Directors has authorized a stock repurchase program on Tuesday, August 15th that permits the company to repurchase 4,000,000 outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through a tender offer. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: “Braden Michael Leonard Sells 1,695,305 Shares of ProPhase Labs, Inc. (PRPH) Stock” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Receive News & Stock Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related stocks with our FREE daily email newsletter.